In this study, we set out to develop a CDtargeting probe for high-contrast noninvasive in vivo positron emission tomog. YY, an anti-CD monoclonal antibody, was employed as a targeting mol. Owing to such marked accumulation, tumor delineation was successful by both PET and NIRF, which facilitated the fluorescence image-guided resection of orthotopic HepG2 tumors, despite the relatively high liver background. Ex vivo biodistribution and immunofluorescent staining corroborated the accuracy of the imaging data and correlated tracer uptake with in situ CD expression.
CDtargeted mol. CD endoglin is an independent marker for poor prognosis in more than 10 solid tumor types. The goal of this study was to develop a CDspecific agent for both positron emission tomog. Another chimeric antibody, cetuximab, was used as an isotype-matched control. FACS anal. Blocking expts. Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye CW Mol.
Pharmaceutics , 9 8 — 49 DOI: American Chemical Society. Metastatic breast cancer is incurable.
- Supporting Language and Communication: A Guide for School Support Staff (Supporting Learning Professionally)?
- Information Visualization, Second Edition: Perception for Design.
- Radioactivity in the Environment, Volume 16: Environmental Radionuclides (Tracers and Timers of Terrestrial Processes)?
- School Violence and Primary Prevention.
- Fundamentals of Tibetan Buddhism (Crossing Press Pocket Guides)!
The goal of this study was to develop a positron emission tomog. Luciferase-transfected 4T1 murine breast cancer cells were injected i. Bioluminescence imaging BLI was carried out to noninvasively monitor the lung tumor burden. Broad clin.
Table of contents
Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess J. Methods , 72 1 77 — 89 DOI: Conjugates of monoclonal antibodies with radioactive isotopes, drugs, or toxins have great potential for specific radiolocalization and inactivation of tumor cells. Because the conjugation procedure may adversely alter the antibody, quality-control procedures must be applied to det.
One such property is how much of the conjugated antibody is able to bind to the relevant antigen.
An Intraoperative Beta−Probe For Cancer Surgery
Based on theor. This ensures that the true value of the immunoreactive fraction is obtained, as opposed to the apparent immunoreactive fraction detd. The described assay is based on a double-inverse plot of the binding data which may be considered a modification of the Lineweaver-Burk plot. The method involves I- and In-labeling of the 2 monoclonal antibodies T and 9.
For properly performed conjugation procedures, immunoreactive fractions of about 0. Due to its principle of detg. It can be used as a quality control procedure for radiolabeled antibodies. Under certain conditions, this procedure is also applicable for quality control of drug- and toxin-conjugated monoclonal antibodies.
Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G Anticancer Res. Steffens, Martijn G. International Institute of Anticancer Research. However, tumor uptake decreased at higher mAb G doses, suggesting satn. In this immunohistochem. Three days post injection mice were killed and the tumors were removed. Free G antigen sites, i. Distinct staining of the G antigen was obsd.
The results of this study indicate that satn. Apparently, all antigenic determinants present on the RCC tumor cells were targeted, while previous preclin. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? Tummers, Quirijn R.
Baptist M. Public Library of Science. Objective: In ovarian cancer, two of the most important prognostic factors for survival are completeness of staging and completeness of cytoreductive surgery. Therefore, intra-operative visualization of tumor lesions is of great importance. The aim of this study was to det. Methods: Ten patients suspected of ovarian cancer scheduled for staging or cytoreductive surgery were included. Patients received 20 mg ICG i. Results: 6 out of 10 patients had malignant disease of the ovary or fallopian tube, of which 2 had metastatic disease outside the pelvis.
Eight metastatic lesions were detected in these 2 patients, which were all NIR fluorescent. However, 13 non-malignant lesions were also NIR fluorescent, resulting in a false-pos. There was no significant difference in tumor-to-background ratio between malignant and benign lesions 2. Conclusions This is the first clin.
Despite detection of all malignant lesions, a high false-pos. The need for tumor-specific intraoperative agents remains. Unfortunately, predicting an accurate and reliable therapeutic response remains a challenge on a per-patient basis.
Although significant efforts have been invested in understanding EGFR-mediated changes in cell signaling related to treatment efficacy, the delivery and histol. Clearly, optical mol. Rosenthal, Eben L. Purpose: Pos. Unfortunately, surgeons remove cancer in the same manner they have for a century with complete dependence on subjective tissue changes to identify cancer in the operating room. To effect change, we hypothesize that EGFR can be targeted for safe and specific real-time localization of cancer. Safety and pharmacokinetic data were obtained out to 30 days after infusion.
Multi-instrument fluorescence imaging was performed in the operating room and in surgical pathol. Results: There were no grade 2 or higher adverse events attributable to cetuximab-IRDye Fluorescence imaging with an intraoperative, wide-field device successfully differentiated tumor from normal tissue during resection with an av. Optical imaging identified opportunity for more precise identification of tumor during the surgical procedure and during the pathol. Fluorescence levels pos. Conclusions: We demonstrate for the first time that com. Clin Cancer Res; 21 16 ; We hypothesized that molecular imaging with a fluorescent probe to pulmonary adenocarcinomas could enhance residual tumor during resection.
Optimal dose and time of injection was established. Margin detection was compared using traditional methods versus molecular imaging. A pilot study was then performed in three humans with lung adenocarcinoma.
US6989140B2 - Methods for cancer imaging - Google Patents
Fluorescence peaked at 2 h and was not improved beyond 0. The fluorescent probe visually enhanced all human tumors with a mean TBR of 3. Aims Tumor-specific targeted imaging is rapidly evolving in cancer diagnosis. Expression was weak or moderate. In breast cancer, neg. Hoogstins, Charlotte E. Purpose: Completeness of cytoreductive surgery is a key prognostic factor for survival in patients with ovarian cancer.
The ability to differentiate clearly between malignant and healthy tissue is essential for achieving complete cytoredn. Using current approaches, this differentiation is often difficult and can lead to incomplete tumor removal. Near-IR fluorescence imaging has the potential to improve the detection of malignant tissue during surgery, significantly improving outcome. Design: We first performed a randomized, placebo-controlled study in 30 healthy volunteers. Four single increasing doses of OTL38 were delivered i.
Next, using the results of the first study, three doses were selected and administered to 12 patients who had epithelial ovarian cancer and were scheduled for cytoreductive surgery.
We measured tolerability and blood pharmacokinetics, as well as the ability to detect the tumor using intraoperative fluorescence imaging. Results: I. In 12 patients with ovarian cancer, OTL38 accumulated in folate receptor alpha-pos. Conclusions: This study demonstrates that performing real-time intraoperative near-IR fluorescence imaging using a tumor-specific agent is feasible and potentially clin.
Clin Cancer Res; 22 12 ; Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17 Oncotarget , 7 22 — 55 DOI: Oncotarget , 7 22 , ISSN:. Our objective was to evaluate EC17 in a larger group of ovarian cancer patients.